Quote:

---

Ohm: Once LL gets FDA approval for one indication, let's assume it's MSS mCRC, doesn't that open the door for oncologists to use it off-label for other types of solid tumor cancers? What hurdles would an oncologist have to overcome to do that?

---

There would be no burden to the physician, they would just have to write the prescription. The patient would most likely be stuck for the full price of the drug since insurance won't cover the cost of off-label use.